Why does immunotherapy work for some cancers and not others?
A drug designer explains what actually decides whether immunotherapy works. The immunology is excellent; the advice about timing it alongside chemotherapy is contested.
What this episode covers
- Whether immunotherapy works depends on your tumour's biology, not on whether the cancer is 'a melanoma' or 'a breast cancer'.
- Three things must line up: an immune cell that recognises the cancer, enough signal to switch it on, and the brakes released.
- The speaker argues chemotherapy and immunotherapy pull against each other when given together, which is a real research question, but one where approved combinations still improved survival.
Confidence in this episode
Everything about how much to believe this episode, in one place.
Strong confidence in the immunology — checkpoints, biomarkers, and why response varies. Low confidence in the practical advice to quiet your immune system around chemotherapy or to change your steroid dose.
- Immune checkpoints such as PD-1 are real, and blocking them is an established cancer treatment.
- Whether immunotherapy can work depends on your tumour's biology, not just the cancer's name.
- Some chemotherapy drugs do suppress immune function, because activated immune cells divide fast like cancer cells.
- That giving chemotherapy and immunotherapy together is a mistake. Several approved combinations improved survival in trials.
- The specific advice to take high-dose turmeric or concentrated vitamin D around infusions.
- Asking to reduce steroids that were prescribed alongside immunotherapy.
- Whether the tumour-marker test he describes is available or useful in practice.
Why it matters
People are often told immunotherapy works for melanoma and does not work for breast cancer, and left there. This episode explains what actually decides it, which turns a label into a question you can ask. That part is genuinely useful. The same episode also suggests adjusting your supplements and steroids around treatment, which is where a mechanism argument starts competing with trial evidence, and where the stakes are highest.
What stands out
- The cancer's name doesn't decide it — response depends on what your tumour displays on its surface, not the diagnosis label (established oncology; his own framing).
- Immune cells look like cancer to chemotherapy — activated immune cells divide fast and burn sugar the same way, so drugs aimed at fast-dividing cells hit them too (established immunology).
- Not everything called immunotherapy is one — some antibody drugs are made using the immune system but never switch yours on (established).
Best-supported action
The single highest-leverage move from this episode, anchored in the strongest evidence the speaker presents.
Ask your oncologist what your tumour's markers show, because those — not the name of the cancer — decide whether a given immunotherapy can work for you at all.
Where to start
Small low-friction starters covering the main moves from this episode.
- Ask what your tumour's biomarkers showed.
- Tell your care team about any supplements before infusion days.
- Ask why each drug in your regimen is there.
Other supported actions
Further actions discussed in this episode, ordered from strongest to weakest evidence. This is one expert's view, the full topic compares and ranks across experts.
- Ask whether your tumour has been tested for the markers that predict immunotherapy response, such as PD-L1.Strong evidence
- Tell your oncologist about every supplement you take, especially around infusion days, since some quiet the immune system and others stimulate it.Strong evidence
- If one checkpoint drug has not worked, ask whether a different type of immunotherapy releases a different brake.Moderate evidence
Full context, impact ratings, and timing — available in related topics
Questions to take to your doctor
- Given my tumour's biomarkers, which immunotherapy could actually work for me?
- Given my regimen, is there a reason the steroids and the immunotherapy are given together?
- Given what I take, could any of my supplements interfere around infusion days?
Full doctor prep with ranked questions available in the full topic page
Context
Cancer drug designer (a PhD scientist, not a physician) who explains the biology of supplements and treatments and is developing an immunotherapy. Strongest on mechanisms and on the real risks of supplement-treatment interactions; goes beyond established evidence with specific protocols for which cancers benefit and how to dose curcumin, and promotes a paid consulting service. Treat the mechanisms as informative and the specific protocols as his interpretation, to check with an oncologist.
This episode does not prove that chemotherapy and immunotherapy should not be given together. Several combinations are approved precisely because trials showed people lived longer, and the speaker acknowledges this is how the trials were run. His argument is mechanistic, and mechanism alone does not overturn outcome data.
The specific suggestions — high-dose turmeric or concentrated vitamin D around infusions, or asking to reduce prescribed steroids — are his own reasoning rather than established practice, and some involve doses above standard limits. He is a scientist, not an oncologist, and says so himself.
He also works with paying clients on treatment optimisation, which is worth knowing. None of this is a reason to change or stop cancer treatment on your own.
Overall evidence profile: mainstream immunology explained in depth, plus the speaker's own mechanistic reasoning and consulting experience, not trial evidence for the protocol changes he suggests.
Where people go wrong
- Taking supplements that quiet or boost the immune system around infusion days without telling your oncologist.Timing can matter during cancer treatment, which is why your oncology team should know about every supplement you take before you change anything.
- Asking to drop steroids or change your regimen based on a mechanism argument.Steroids are often there for a reason, and the combinations criticised here have trial evidence behind them.
What to expect over time
- Before treatmentThe useful questions are what your tumour's markers show and why each drug in your regimen is there.
- During treatmentSome interactions between supplements and cancer therapy are well established, while others remain uncertain. That is why it is important to tell your care team about everything you take.
- If it isn't workingNot responding to one checkpoint drug does not rule out a different type, and that is a conversation worth having.